Abstract
Context: Pruritus associated with hepatic or renal failure can be a troublesome symptom, refractory to treatment and associated with significant physical and emotional distress and a reduction in quality of life for patients already burdened with chronic disease. Serotonin has been implicated as a possible pathological mediator, and, therefore, 5HT3 antagonists have been suggested as a possible therapeutic intervention. Objectives: This review of the literature systematically explores the role of ondansetron in the management of cholestatic or uremic pruritus. Methods: Electronic databases were systematically searched for randomized controlled trials examining the role of ondansetron in cholestatic or uremic pruritus between 1966 and 2008. Results: Five randomized controlled trials were included in this systematic review: three for cholestatic pruritus and two for uremic pruritus. All trials examined ondansetron vs. placebo, with differing treatment protocols. Overall, three studies showed no benefit to ondansetron over placebo; however, two studies in cholestatic pruritus showed small reductions in pruritus with questionable clinical significance. Conclusion: Ondansetron was demonstrated to have negligible effect on cholestatic or uremic pruritus on the basis of a limited number of studies.
| Original language | English |
|---|---|
| Pages (from-to) | 725-730 |
| Number of pages | 6 |
| Journal | Journal of Pain and Symptom Management |
| Volume | 44 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Nov 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 5HT antagonists
- cholestasis
- hepatic failure
- itch
- Ondansetron
- pruritus
- renal failure
- uremia
Fingerprint
Dive into the research topics of 'The role of ondansetron in the management of cholestatic or uremic pruritus - A systematic review'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver